

1636 Page



**Sterne Kessler  
Goldstein Fox**  
ATTORNEYS AT LAW

Robert Greene Sterne  
Edward J. Kessler  
Jorge A. Goldstein  
David K.S. Cornwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michele A. Cimbala  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Steffe  
Michael Q. Lee  
Steven R. Ludwig  
John M. Covert  
Linda E. Alcorn  
Robert C. Millonig  
Lawrence B. Bugaisky  
Donald J. Featherstone  
Michael V. Messinger

Judith U. Kim  
Timothy J. Shea, Jr.  
Patrick E. Garrett  
Heidi L. Kraus  
Edward W. Yee  
Albert L. Ferro\*  
Donald R. Banowitz  
Peter A. Jackman  
Molly A. McCall  
Teresa U. Medler  
Jeffrey S. Weaver  
Kendrick P. Patterson  
Vincent L. Capuano  
Eldora Ellison Floyd  
Thomas C. Fiala  
Brian J. Del Buono  
Virgil Lee Beaston\*  
Kimberly N. Reddick

Theodore A. Wood  
Elizabeth J. Haanes  
Bruce E. Chalker  
Joseph S. Ostroff  
Frank R. Cottingham  
Christine M. Lhulier  
Rae Lynn Pregarman  
Jane Shershenovich\*  
Lawrence J. Carroll\*  
George S. Bardmesser  
Daniel A. Klein\*  
Rodney G. Maze  
Jason D. Eisenberg  
Michael D. Specht  
Andrea L. Kamage  
Tracy L. Muller\*  
Jon E. Wright\*  
LuAnne M. Yuricek\*

John J. Figueroa  
Ann E. Summerfield  
**Registered Patent Agents\***  
Karen R. Markowicz  
Nancy J. Leith  
Helene C. Carlson  
Gaby L. Longworth  
Matthew J. Dowd  
Aaron L. Schwartz  
Angelique G. Uy  
Mary B. Tung  
Katrina Y. Pei  
Bryan L. Skelton  
Robert A. Schwartzman  
Timothy A. Doyle  
Jennifer R. Mahalingappa

Teresa A. Colella  
Jeffrey S. Lundgren  
Victoria S. Rutherford  
Eric D. Hayes

**Of Counsel**  
Kenneth C. Bass III  
Evan R. Smith

\*Admitted only in Maryland  
\*Admitted only in Virginia  
•Practice Limited to  
Federal Agencies

October 21, 2003

**WRITER'S DIRECT NUMBER:**

(202) 772-8560

**INTERNET ADDRESS:**

RESMOND@SKGF.COM

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**Art Unit 1636**

Re: U.S. Utility Patent Application  
Appl. No. 09/869,159; Filed: August 15, 2001  
For: **Assay for Identifying Compounds Which Affect Stability of mRNA**  
Inventors: KASTELIC *et al.*  
Our Ref: 1556.0290000/RWE/JKM

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Letter Regarding Ownership of United States Patent Application No. 09/869,159;
2. Assignment to Novation Pharmaceuticals Inc. (Declaration of Dominique Cheneval and Tania Kastelic with Exhibit "A" - Assignment to Novartis AG; Exhibit "B" - Affidavit with Assignment to Novartis AG; Exhibit "C" - Certificate of Corrections from Canadian Patent Office; Exhibit "D" - Assignment between Novartis AG and Novation Pharmaceuticals Inc.; and Exhibit "E" - Assignment to Novation Pharmaceuticals Inc. with acknowledgments of Declaration of inventors; and
3. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents

October 21, 2003

Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert W. Esmond  
Attorney for Applicants  
Registration No. 32,893

RWE/JKM/acr  
Enclosures

SKGF\_DC1:190373.1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

KASTELIC et al.

Appl. No. 09/869,159

Filed: August 15, 2001

For: **Assay for Identifying Compounds  
Which Affect Stability of mRNA**

Confirmation No. 9266

Art Unit: 1636

Examiner: Qian, C.X.

Atty. Docket: 1556.0290000/RWE/JKM

**Letter Regarding Ownership of United States Patent  
Application No. 09/869,159**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

On August 15, 2001, Applicants filed the following documents in the above captioned application: a Certificate Under 37 C.F.R. § 3.73(b), with a copy of an Assignment from the inventors to Novation Pharmaceuticals Inc.; and a Power of Attorney from Assignee with Delegation.

It has since come to Applicants' undersigned representative's attention that the inventor's rights in the priority applications related to the above captioned application were originally assigned by the inventors to Novartis AG, and then subsequently transferred to Novation Pharmaceuticals Inc. In order to clarify the chain of title for the above captioned application, Applicants file herewith copies of the following documents:

Declaration of Dominique Cheneval and Tania Kastelic with Exhibit "A" - Assignment to Novartis AG; Exhibit "B"- Affidavit with Assignment to Novartis AG; Exhibit "C" - Certificate of Corrections from Canadian Patent Office; Exhibit "D" - Assignment between Novartis AG and Novation Pharmaceuticals Inc.; and Exhibit

"E" - Assignment to Novation Pharmaceuticals Inc. with acknowledgments of Declaration of inventors.

Consideration of this letter and of the submitted documents and making the same of record in the prosecution of the above-captioned application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert W. Esmond  
Attorney for Applicants  
Registration No. 32,893

Date: October 21, 2003

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600